|
Balance Sheet Cash Flow Statement 60 Hampshire St. Cambridge, MA 02139 MA Tel. 617-995-9800 Fax 617-995-9801 |
Type: Public
On the web:
http://www.idenix.com
Employees:
173
Employee growth: (21.0%)
Idenix Pharmaceuticals is not suffering from any identity crisis -- it is clear in its focus on identifying treatments for life-threatening viruses. The biopharmaceutical firm is developing orally administered drugs to combat chronic hepatitis C (HCV) and HIV. Its lead HIV product candidate is in early clinical stages; its HCV candidates are in preclinical testing. Most are intended to be taken in combination with other therapeutic agents to improve efficacy and convenience. Under a development and commercialization agreement, Novartis has the option to license any of the product candidates developed by Idenix. Novartis owns 56% of Idenix.
Key numbers for fiscal year ending December, 2008:
Sales: $10.0M
One year growth: (85.2%)
Net income: ($70.2)M
Officers:
Chairman, President, and CEO: Jean-Pierre Sommadossi
CFO and Treasurer: Ronald C. (Ron) Renaud Jr.
VP Corporate Communications: Amy Sullivan
Competitors:
Bristol-Myers Squibb
Gilead Sciences
GlaxoSmithKline
